Eagle Financial Publications
Ned Piplovic is the assistant editor of website content at Eagle Financial Publications. He graduated from Columbia University with a Bachelor's degree in Economics and Philosophy. Prior to joining Eagle, Ned spent 15 years in corporate operations and financial management. Ned writes for www.DividendInvestor.com and www.StockInvestor.com.
Despite a significant economic downturn and a stock market pullback, a few large-cap companies in the healthcare sector managed to hold onto their positive total returns over the trailing 12-month period, observes Ned Piplovic, income expert and editor of DividendInvestor.
The PIMCO Real Estate Real Return Strategy Fund (PETCX) seeks to capture the performance potential through derivative exposure to the Dow Jones U.S. Select Real Estate Investment Trust (REIT) Index, observes Ned Piplovic, editor of DividendInvestor.
Income investors can leverage the increased demand for healthcare into strong total returns, explains Ned Piplovic, editor of DividendInvestor. Here, he reviews two global pharmaceutical firms that are attractive for investors seeking both growth and income.
After a relatively soft performance in 2018, semiconductor companies delivered significantly better results in 2019 and might be poised to extend that uptrend into 2020, especially semiconductor dividend stocks with above-average yields, explains Ned Piplovic, an editor at DividendInvestor.